Cataract surgery is one of the most frequently performed procedures in medicine, and as surgical volumes climb worldwide, the market around managing its complications, devices, and intraocular lenses (IOLs) is expanding just as fast. According to DelveInsight's "Cataract Surgery Complications Market Insights, Epidemiology, and Market Forecast – 2034" report, the cataract surgery complications market is projected to grow steadily through 2034, propelled by rising surgical volume, an aging population, and a maturing pipeline of anti-inflammatory and anti-infective therapies across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

This article breaks down what's driving the cataract surgery market, cataract surgery devices market, and post-operative cataract surgery inflammation market, along with the companies and lens-adjacent innovations worth tracking in 2026.

Why the Cataract Surgery Market Is Growing

Cataracts remain one of the most common age-related eye conditions, and the sheer scale of annual procedures illustrates the size of the opportunity. DelveInsight estimates that approximately 4 million cataract surgeries were performed in the U.S. in 2024, alongside roughly 940,000 in Germany and 1.5 million in Japan. As surgical volume rises, so does the incidence of associated complications inflammation, infection, posterior capsular rupture, cystoid macular edema, and endophthalmitis among them.

Several factors are fueling this expanding market:

1. Rising surgical volumes worldwide, driven by the sheer prevalence of age-related cataracts.

2. An expanding geriatric population, increasing the pool of patients at risk for post-surgical complications.

3. Ocular comorbidities such as diabetes, glaucoma, and uveitis, which raise complication risk and surgical complexity.

4. Advancements in postoperative care technologies, including improved ocular imaging and IOL monitoring.

5. Growing adoption of minimally invasive and premium IOL procedures, which while reducing certain risks can introduce new, specific complication profiles.

6. Increasing healthcare spending and access to eye care, especially across developing regions.

Post-Operative Cataract Surgery Inflammation Market: The Core Battleground

Inflammation control is central to the post-operative cataract surgery inflammation market, since even routine procedures carry a measurable complication rate. DelveInsight's epidemiological findings underscore this: in the U.S., intraoperative adverse events included capsular tears in 0.55% of cases and vitreous loss in 0.34%, while postoperative events included iritis (1.53%), corneal edema (0.53%), and retinal tear or detachment (0.14%). Acute-onset endophthalmitis occurred in roughly 0.04% of U.S. cataract surgeries between 2013 and 2017. In the UK, postoperative complications affect an estimated 2–14.7% of cases, with posterior capsule opacification developing in nearly one in five eyes. Japan reported postoperative endophthalmitis at 0.025% and early postoperative intraocular pressure elevation in 6.3% of patients.

These figures explain why inflammation and infection management remain the primary commercial focus of the cataract surgery complications market, rather than the lens hardware itself.

Marketed and Emerging Therapies

Currently marketed treatments anchoring the market include DEXTENZA (dexamethasone ophthalmic insert) from Ocular Therapeutix, a corticosteroid insert approved for post-surgical inflammation and pain that received expanded pediatric approval in April 2025, and NEVANAC/ILEVRO (nepafenac ophthalmic suspension) from Harrow, an NSAID prodrug used for post-cataract inflammation control.

The emerging pipeline is where the most differentiated innovation is happening:

1. Oculis' OCS-01 is a once-daily, high-concentration, preservative-free dexamethasone eye drop built on the company's OPTIREACH technology. It met both primary endpoints in the Phase III OPTIMIZE-1 trial for post-cataract surgery inflammation and pain, with an NDA filing for a related indication (DME) expected in the second half of 2026, followed by an ocular surgery submission.

2. Salvat's SVT-15473, a clobetasol propionate nanoemulsion built on IMPACT-SVT technology, posted positive pooled Phase III results and is now being evaluated in the Phase III CLOSE-3 trial for pediatric post-cataract inflammation in Europe.

3. VivaVision Biotech's VVN461, a dual JAK1/TYK2 inhibitor, received positive FDA feedback in June 2025 confirming its Phase II trial can serve as one of two pivotal studies for NDA submission reducing the remaining pathway to a single additional Phase III trial.

Leading companies named across the cataract surgery complications landscape include Bausch & Lomb Incorporated, Reata Pharmaceuticals, AbbVie, Eyegate Pharmaceuticals, Alcon Research, Regeneron Pharmaceuticals, Emmecell, Genentech, and Oculis, alongside Ocular Therapeutix, Harrow, Salvat, and VivaVision Biotech.

Cataract Surgery Devices Market and Lens Brands: What the Data Actually Shows

Searches for "cataract surgery lens brands," "best lens brand for cataract surgery," and "best imported lens for cataract surgery" often overlap with a related but distinct category: intraocular lens (IOL) technology and the broader cataract surgery devices market. DelveInsight's complications-focused report does touch on this adjacency noting that growing adoption of minimally invasive and premium IOL procedures is a market driver, and pointing to the intraocular lens market as a related coverage area but its core dataset centers on the drugs and therapies used to manage surgical complications, not head-to-head lens brand comparisons.

For buyers and clinicians specifically evaluating the "best lens brand for cataract surgery" or the best imported lens for cataract surgery, that decision typically depends on individual patient anatomy, astigmatism correction needs, and premium versus monofocal/multifocal lens choice factors best discussed with an ophthalmic surgeon rather than determined by market share data alone. Companies active in both the IOL device space and the broader ophthalmic therapeutics landscape including Alcon, Bausch & Lomb, and AbbVie are worth watching as this device and drug ecosystem converges.

Unmet Needs Still Shaping Cataract Surgery Marketing and Innovation

Despite decades of surgical refinement, DelveInsight's KOL interviews conducted across institutions including the American Society of Cataract and Refractive Surgery, University Eye Hospital Heidelberg, and Rothschild Foundation Hospital highlight persistent gaps: limited standardized protocols for early complication detection, inconsistent risk stratification for high-risk patients, and existing prophylactic options that still fail to avert some vision-threatening outcomes. This unmet need is precisely what is fueling continued R&D investment and shaping cataract surgery marketing narratives around "next-generation," sustained-release, and targeted anti-inflammatory formulations.

Market Outlook Through 2034

The United States is expected to retain the largest share of the 7MM cataract surgery complications market through the forecast period, driven by high procedure volume and higher treatment costs, with continued momentum from new product launches. As premium IOL adoption increases and inflammation-management therapies mature, the broader cataract surgery devices market and post-operative inflammation market are likely to expand in parallel creating opportunities across both the pharmaceutical and device sides of the ecosystem.